DE69637950D1 - Impfstoff bestehend aus auf Aluminium-Phosphat adsorbiertem, konjugiertem Polysaccharid Antigen - Google Patents

Impfstoff bestehend aus auf Aluminium-Phosphat adsorbiertem, konjugiertem Polysaccharid Antigen

Info

Publication number
DE69637950D1
DE69637950D1 DE69637950T DE69637950T DE69637950D1 DE 69637950 D1 DE69637950 D1 DE 69637950D1 DE 69637950 T DE69637950 T DE 69637950T DE 69637950 T DE69637950 T DE 69637950T DE 69637950 D1 DE69637950 D1 DE 69637950D1
Authority
DE
Germany
Prior art keywords
aluminum
polysaccharide antigen
vaccine consisting
conjugated polysaccharide
phosphate adsorbed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637950T
Other languages
German (de)
English (en)
Inventor
Julien Peetermans
Pierre Hauser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69637950(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9512827.8A external-priority patent/GB9512827D0/en
Priority claimed from GBGB9513443.3A external-priority patent/GB9513443D0/en
Priority claimed from GBGB9525657.4A external-priority patent/GB9525657D0/en
Priority claimed from GBGB9606032.2A external-priority patent/GB9606032D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of DE69637950D1 publication Critical patent/DE69637950D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69637950T 1995-06-23 1996-06-19 Impfstoff bestehend aus auf Aluminium-Phosphat adsorbiertem, konjugiertem Polysaccharid Antigen Expired - Lifetime DE69637950D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9512827.8A GB9512827D0 (en) 1995-06-23 1995-06-23 Vaccines
GBGB9513443.3A GB9513443D0 (en) 1995-07-01 1995-07-01 Vaccines
GBGB9525657.4A GB9525657D0 (en) 1995-12-15 1995-12-15 Vaccines
GBGB9606032.2A GB9606032D0 (en) 1996-03-22 1996-03-22 Vaccines

Publications (1)

Publication Number Publication Date
DE69637950D1 true DE69637950D1 (de) 2009-07-23

Family

ID=27451299

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69637950T Expired - Lifetime DE69637950D1 (de) 1995-06-23 1996-06-19 Impfstoff bestehend aus auf Aluminium-Phosphat adsorbiertem, konjugiertem Polysaccharid Antigen
DE69612198T Expired - Lifetime DE69612198T3 (de) 1995-06-23 1996-06-19 Eine Impfstoffzusammensetzung, bestehend aus einem Haemophilus influenzae B Polysaccharid Antigen-Konjugat adsorbiert an Aluminiumphosphat

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69612198T Expired - Lifetime DE69612198T3 (de) 1995-06-23 1996-06-19 Eine Impfstoffzusammensetzung, bestehend aus einem Haemophilus influenzae B Polysaccharid Antigen-Konjugat adsorbiert an Aluminiumphosphat

Country Status (35)

Country Link
EP (2) EP1082965B1 (https=)
JP (2) JP4850987B2 (https=)
KR (1) KR100425929B1 (https=)
CN (1) CN1146444C (https=)
AP (1) AP812A (https=)
AR (1) AR003006A1 (https=)
AT (2) ATE199831T1 (https=)
AU (1) AU696338B2 (https=)
BG (1) BG62720B1 (https=)
BR (1) BRPI9609414B8 (https=)
CA (1) CA2222455C (https=)
CY (1) CY2297B1 (https=)
CZ (1) CZ288908B6 (https=)
DE (2) DE69637950D1 (https=)
DK (2) DK1082965T3 (https=)
DZ (1) DZ2055A1 (https=)
EA (1) EA199700413A1 (https=)
EG (1) EG25924A (https=)
ES (2) ES2325301T3 (https=)
GR (1) GR3036088T3 (https=)
HU (1) HU224514B1 (https=)
IL (1) IL122588A (https=)
MA (1) MA23918A1 (https=)
MY (1) MY114786A (https=)
NO (1) NO325169B1 (https=)
NZ (1) NZ312132A (https=)
OA (1) OA10646A (https=)
PE (1) PE11298A1 (https=)
PL (1) PL184872B1 (https=)
PT (2) PT1082965E (https=)
SI (2) SI1082965T1 (https=)
SK (1) SK176197A3 (https=)
TR (1) TR199701682T1 (https=)
TW (1) TW467746B (https=)
WO (1) WO1997000697A1 (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48365A1 (en) 1992-05-23 1998-04-17 Smithkline Beecham Biolog Combined vaccines comprising hepatitis b surface antigen and other antigens
US6355450B1 (en) 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
US6468765B1 (en) 1995-04-21 2002-10-22 Human Genome Sciences, Inc. Selected Haemophilus influenzae Rd polynucleotides and polypeptides
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
PL184872B1 (pl) * 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
DE69736709T2 (de) * 1996-07-02 2007-10-04 Sanofi Pasteur Ltd., Toronto Vielwertige dtp-polio-impfstoffe
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
US6585973B1 (en) 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
CZ20024224A3 (cs) * 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek
SI21352A (sl) 2001-01-23 2004-06-30 Aventis Pasteur Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
CA2503946C (en) 2002-11-01 2016-08-16 Glaxosmithkline Biologicals S.A. Drying process
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
EP1667712B1 (en) * 2003-10-02 2010-07-21 GlaxoSmithKline Biologicals S.A. B. pertussis antigens and use thereof in vaccination
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
NZ546430A (en) 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
CA2605179A1 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics, Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
PL2004225T3 (pl) 2006-03-22 2012-09-28 Novartis Ag Schematy immunizacji koniugatami meningokokowymi
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
ES2555786T3 (es) 2007-06-04 2016-01-08 Glaxosmithkline Biologicals Sa Formulación de vacunas contra la meningitis
FR2918671B1 (fr) 2007-07-10 2010-10-15 Sanofi Pasteur Milieu de culture d'haemophilus influenzae type b.
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
TW201043267A (en) * 2009-03-19 2010-12-16 Intervet Int Bv In situ constituting a vaccine for administration to a predetermined herd of animals
EP2411048B1 (en) * 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
EP2661277A2 (en) 2011-01-05 2013-11-13 Bharat Biotech International Limited A combination heptavalent vaccine
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
BR112014017898B1 (pt) 2012-02-01 2021-10-13 Glaxosmithkline Biologicals S.A. Processo de fermentação
CN104487086B (zh) * 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 无动物源的不含酒精的疫苗组合物及其制备方法
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
EP2906239A1 (en) 2012-10-12 2015-08-19 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
MX2016001695A (es) 2013-08-05 2016-05-02 Glaxosmithkline Biolog Sa Composiciones inmunogenas de combinacion.
US11219680B2 (en) 2017-02-24 2022-01-11 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier
CN111032078A (zh) 2017-07-18 2020-04-17 血清研究所印度私人有限公司 具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法
EA202190778A1 (ru) 2018-10-12 2021-08-05 Серум Инститьют Оф Индия Прайват Лтд Композиция комбинированной вакцины, содержащая уменьшенную дозу инактивированного полиовируса, и способ её получения
WO2020236973A1 (en) 2019-05-20 2020-11-26 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines
CN111658617A (zh) * 2019-10-14 2020-09-15 四川大学 一种含铝佐剂疫苗的冻干制剂及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
ATE128628T1 (de) * 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ES2204900T3 (es) 1992-02-11 2004-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Estructura inmuinogena de doble vector.
SG48365A1 (en) 1992-05-23 1998-04-17 Smithkline Beecham Biolog Combined vaccines comprising hepatitis b surface antigen and other antigens
DE69323264D1 (de) * 1992-10-27 1999-03-11 American Cyanamid Co Pädiatrische Kombinationsvakzine mit verbesserter Immunogenizität jeder Vakzine komponente
PL184872B1 (pl) * 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie

Also Published As

Publication number Publication date
WO1997000697A1 (en) 1997-01-09
DE69612198T2 (de) 2001-11-08
HK1009764A1 (en) 1999-06-11
IL122588A0 (en) 1998-06-15
CY2297B1 (en) 2003-07-04
NO325169B1 (no) 2008-02-11
NZ312132A (en) 1999-04-29
EP0833662B2 (en) 2011-01-26
MX9710521A (es) 1998-08-30
AU696338B2 (en) 1998-09-10
DK0833662T4 (da) 2011-02-28
EP1082965A1 (en) 2001-03-14
SI0833662T1 (en) 2001-12-31
KR19990028336A (ko) 1999-04-15
MA23918A1 (fr) 1996-12-31
MY114786A (en) 2003-01-31
DK1082965T3 (da) 2009-07-27
HK1037516A1 (en) 2002-02-15
EG25924A (en) 2012-10-22
ES2325301T3 (es) 2009-09-01
PE11298A1 (es) 1998-03-20
BG62720B1 (bg) 2000-06-30
CA2222455A1 (en) 1997-01-09
EP1082965B1 (en) 2009-06-10
DE69612198D1 (de) 2001-04-26
DZ2055A1 (fr) 2002-10-20
GR3036088T3 (en) 2001-09-28
BRPI9609414B8 (pt) 2021-05-25
PL184872B1 (pl) 2003-01-31
HUP9900061A1 (hu) 1999-04-28
EP0833662A1 (en) 1998-04-08
DK0833662T3 (da) 2001-07-09
SK176197A3 (en) 1998-07-08
ES2157447T5 (es) 2011-04-29
ATE199831T1 (de) 2001-04-15
ATE433329T1 (de) 2009-06-15
ES2157447T3 (es) 2001-08-16
KR100425929B1 (ko) 2004-05-31
BR9609414A (pt) 1999-05-18
PT833662E (pt) 2001-09-28
CN1146444C (zh) 2004-04-21
SI1082965T1 (sl) 2009-08-31
JPH11507935A (ja) 1999-07-13
CN1188418A (zh) 1998-07-22
DE69612198T3 (de) 2011-08-18
JP2008120833A (ja) 2008-05-29
OA10646A (en) 2002-09-18
BG102146A (en) 1998-10-30
NO976035L (no) 1998-02-16
EP0833662B1 (en) 2001-03-21
IL122588A (en) 2001-12-23
CA2222455C (en) 2013-05-28
NO976035D0 (no) 1997-12-22
TR199701682T1 (xx) 1998-06-22
CZ418997A3 (cs) 1998-06-17
AP9701159A0 (en) 1998-01-31
AP812A (en) 2000-02-24
HUP9900061A3 (en) 2000-03-28
SI0833662T2 (sl) 2011-06-30
AU6359196A (en) 1997-01-22
PL324242A1 (en) 1998-05-11
CZ288908B6 (cs) 2001-09-12
PT1082965E (pt) 2009-07-01
JP4850987B2 (ja) 2012-01-11
HU224514B1 (hu) 2005-10-28
AR003006A1 (es) 1998-05-27
BR9609414B1 (pt) 2013-11-19
TW467746B (en) 2001-12-11
EA199700413A1 (ru) 1998-08-27

Similar Documents

Publication Publication Date Title
DE69637950D1 (de) Impfstoff bestehend aus auf Aluminium-Phosphat adsorbiertem, konjugiertem Polysaccharid Antigen
DE60043930D1 (de) Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
DE69621226D1 (de) Polyolefin-polyamid konjugierter vliesstoff
ATE121947T1 (de) Verbessertes meningokokkale polysaccharidkonjugatvakzin.
EP1027061A4 (en) IMIN-FORMING POLYSACCHARIDES, THEIR PRODUCTION AND USE AS ADDITIVES AND IMMUNO-STIMULATING AGENTS
DZ2026A1 (fr) Compositions vaccinantes.
PT810877E (pt) Vacina da hepatite b
DE69231663D1 (de) Konjugate bestehend aus polysaccharid und protein
IT1272943B (it) Composizioni insetticide labili
IT1274833B (it) Dispositivo di incarto di gruppi di sigarette.
DE69630611D1 (de) Antigenische präparationen
DE69618694D1 (de) N-Acetylpiperazinderivat, antibakteriell und anti-ulcer Medikament
FR2715304B1 (fr) Vaccin anti-allergique.
AU1179695A (en) (vibrio cholerae) bengal serogroup-0139 capsular polysaccharide, protein conjugates thereof and antibodies induced thereby
EP0584212A4 (en) VACCINES COMPRISING A POLYSACCHARIDE ENCAPSULATED IN A LIPOSOME.
DE69925916D1 (de) Immunstimulierende Phellinus ssp. Polysaccharid und Verwendung
FR2731707B1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique
TR199600557A2 (tr) Benzillenmis cis-2,3-epoksisikloalkanoller.
KR960037970U (ko) 절첩식 파이프
FR2769629B1 (fr) Derives de 8-azabicyclo[3.2.1]octane-3-methanamine, leur preparation et leur application en therapeutique
KR970027453U (ko) 부시 성형 장치
BR9603253B1 (pt) derivado de camptotecina e composiÇço farmacÊutica compreendendo o mesmo.
FI951276A7 (fi) Parannettuja ominaisuuksia omaavat vasta-ainekonjugaatit
KR970021397U (ko) 차량용 스프링 브라켓트 구조
IT1282746B1 (it) Compresse masticabili e solubili contenenti n-acetilcisteina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition